Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)

• Status: Completed
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the RAPID STEMI study is to evaluate the feasibility, efficacy, and safety of a pharmacogenetic approach to anti-platelet therapy for the treatment of ST-segment elevation myocardial infarction (STEMI) patients following percutaneous coronary intervention (PCI) using point-of-care genetic testing for the CYP2C19*2, *17, and ABCB1 3435 C>T alleles.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ottawa Heart Institute Research Corporation
• Collaborator: Spartan Bioscience Inc.
• Treatments: Clopidogrel; Prasugrel Hydrochloride; Ticlopidine

Criteria

Inclusion Criteria:

• Males and Females between the ages of 18 and 75 years

• STEMI patients treated with percutaneous coronary intervention

• Able to provide informed consent

• Able to comply with assigned treatment strategy and attend 1 month follow-up visit

Exclusion Criteria:

• Receiving anti-platelet therapy other than aspirin and clopidogrel

• Receiving anti-coagulation with warfarin or dabigatran

• History of stroke or transient ischemic attack

• Platelet count < 100 000/μL

• Known Bleeding Diathesis

• Hematocrit <30% or >52%

• Severe Liver Dysfunction

• Renal Insufficiency (Creatinine Clearance < 30ml/min)

• Pregnant females